Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 9/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6225535 | 0.82 | HRH3 (0.49) | EPHX2HRH3 | |
| SCHEMBL10819391 | 0.81 | HRH3 (0.48) | EPHX2RETHRH3PDE3BPDE3A | |
| SCHEMBL5300149 | 0.79 | ROCK1 (0.56) | HRH3 | |
| SCHEMBL1306480 | 0.79 | CARM1 (0.46) | EPHX2PDE3BPDE3APDE10AAVPR1A | |
| SCHEMBL1307520 | 0.78 | HRH3 (0.58) | HRH3 | |
| SCHEMBL13683393 | 0.78 | EPHX2 (0.44) | EPHX2RETHRH3PDE3BPDE3A | |
| SCHEMBL29605026 | 0.77 | AVPR1A (0.49) | EPHX2AVPR1A | |
| SCHEMBL20266971 | 0.77 | AVPR1A (0.49) | EPHX2AVPR1A | |
| SCHEMBL2743227 | 0.76 | PDE3B (0.50) | EPHX2HRH3PDE3BPDE3APDE10A | |
| SCHEMBL20412701 | 0.76 | EPHX2 (0.49) | EPHX2RETHRH3PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | EPHX2 4068/4885RET 886/4885HRH3 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.